Inspirna Announces Appointment of Karim Benhadji, M.D., as Chief Medical Officer and Retirement of Robert Wasserman, M.D.
The Pharmaceutical Marketing Group
by Admin
2d ago
NEW YORK–(BUSINESS WIRE)–Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today the appointment of Karim Benhadji, M.D., as Chief Medical Officer, effective May 1, 2024. Dr. Benhadji will succeed Robert Wasserman, M.D., who is retiring as Chief Medical Officer and will transition to a role as Advisor to the Company. Dr. Wasserman was appointed Chief Medical Officer of Inspirna (previously Rgenix) in 2019, and oversaw the early clinical development of its lead candidates, ompenaclid (RGX-202) and abequolixron (RGX-104). “Bob wa ..read more
Visit website
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
The Pharmaceutical Marketing Group
by Admin
2d ago
LOS ALTOS, Calif.–(BUSINESS WIRE)–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the expansion of the Company’s leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO). Mr. Hanley brings over twenty-five years of leadership experience in the life sciences industry, with established expertise across corporate operations, product development, strategy, and commercialization, with relevant expertise in CNS/neuroscience-focused companies. As Alto’s COO, Mike will be responsible for new product planning, portfolio strategy, and cross-fun ..read more
Visit website
The Foundation for the National Institutes of Health Announces the Launch of a Public-Private Partnership to Accelerate ALS Diagnosis and Treatment
The Pharmaceutical Marketing Group
by Admin
2d ago
NORTH BETHESDA, Md.–(BUSINESS WIRE)–The Foundation for the National Institutes of Health (FNIH) announces the launch of a public-private partnership to build the largest data source for amyotrophic lateral sclerosis (ALS) and expedite the identification of biomarkers and clinical outcome assessments that would allow earlier diagnosis and accelerated drug development for people living with the disease. ALS is a progressive and ultimately fatal neurological disease with few treatment options and no cure yet. Managed by the FNIH, the Accelerating Medicines Partnership® in Amyotrophic Lateral Scl ..read more
Visit website
CG Life Acquires Berry & Company Public Relations, Further Expanding Strategic Communications Services for BioPharma and Healthcare
The Pharmaceutical Marketing Group
by Admin
2d ago
CHICAGO & NEW YORK–(BUSINESS WIRE)–CG Life, a science-first, tech-enabled agency for life science, has acquired Berry & Company Public Relations, a New York City-based public relations agency focused on service to life sciences and medical technology companies. The acquisition significantly expands the range of CG Life communications expertise and services to support clients in the biopharma and medical sectors. Berry & Company is a specialized PR firm with more than 25 years of experience in healthcare communications. The agency provides a complete range of public relations servi ..read more
Visit website
Be Biopharma Expands Scientific Advisory Board with the Appointment of Cell and Gene Therapy Leader Dr. Paula Cannon
The Pharmaceutical Marketing Group
by Admin
2d ago
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today announced the addition of Paula Cannon, Ph.D., to its Scientific Advisory Board. Dr. Cannon, Distinguished Professor of Molecular Microbiology and Immunology at the Keck School of Medicine of the University of Southern California, was recently appointed President of the American Society for Gene and Cell Therapy (ASGCT). Dr. Cannon will work with other members of the Scientific Advisory Board to provide scientific and clinical guidance ..read more
Visit website
Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC
The Pharmaceutical Marketing Group
by Admin
2d ago
SEONGNAM-SI, South Korea–(BUSINESS WIRE)–Qurient Co. Ltd. (KRX: 115180), a clinical-stage biotech company based in Korea, entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to evaluate Qurient’s proprietary CDK7 inhibitor, Q901, in combination with an antibody drug conjugate (ADC) targeting tumor-associated calcium signal transducer 2 (TROP2) with topoisomerase 1 inhibitor payload for the treatment of small cell lung cancer (SCLC) and other relapsed solid tumors. Q901 is a highly ..read more
Visit website
Milliman Medical Index estimates 2024 cost of healthcare for American individual is $7,151; cost for family of four is $32,066
The Pharmaceutical Marketing Group
by Admin
2d ago
SEATTLE–(BUSINESS WIRE)–Milliman, Inc., a premier global consulting and actuarial firm, today announced the release of the 2024 Milliman Medical Index (MMI), which measures healthcare costs for Americans covered by a typical employer-sponsored health insurance plan. Healthcare costs for the average person increased 6.7% in 2024, with pharmacy costs increasing by 13% and constituting nearly half of this year’s total increase. Healthcare costs for a hypothetical family of four rose to $32,066. “The cost of prescription drugs contributed to about half of this year’s healthcare cost increase,” sa ..read more
Visit website
Edgewood Oncology Announces First Patients Dosed in Phase 2a Study of BTX-A51 in Genetically-Defined Breast Cancer
The Pharmaceutical Marketing Group
by Admin
2d ago
BROOKLINE, Mass.–(BUSINESS WIRE)–Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid tumors, today announced that the first two patients with metastatic breast cancer were treated with BTX-A51, a multi-specific kinase inhibitor of casein kinase 1 alpha (CK1α) and cyclin-dependent kinases 7 and 9 (CDK7 and CDK9), that synergistically targets master regulators of cancer. BTX-A51 is being evaluated in a Phase 2a study for the treatment of estrogen receptor positive / human epidermal growth ..read more
Visit website
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
The Pharmaceutical Marketing Group
by Admin
2d ago
HYDERABAD, India & REYKJAVIK, Iceland–(BUSINESS WIRE)–Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), today announced that the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia ..read more
Visit website
Aulos Bioscience Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany To Study Combination of Bavencio® With AU-007
The Pharmaceutical Marketing Group
by Admin
1w ago
LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced a new collaboration and supply agreement with Ares Trading S.A., a Swiss subsidiary of Merck KGaA, Darmstadt, Germany, for use of Bavencio® (avelumab) in a clinical study of its lead human monoclonal antibody candidate, AU-007. Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will provide Aulos with a free supply of Bavencio to evaluate in combination with AU-007 and low-dose ..read more
Visit website

Follow The Pharmaceutical Marketing Group on FeedSpot

Continue with Google
Continue with Apple
OR